

Connecticut Medicaid P&T Meeting Minutes – December 3, 2009

The meeting started at 6:30 pm

Attendance

Present Members:

Carl Sherter, MD
Eric Einstein, MD
Hilda Slivka, MD
Lester Silberman, MD
Charles Thompson, MD
Lawrence Sobel, RPh
Emmett Sullivan, RPh
Stella Cretella
Elizabeth Rodriguez, RN

DSS:

Evelyn Dudley
Jason Gott
James Zakszewski
Robert Zavoski, MD

Absent Members:

Richard Carbray, Jr. RPh
Peggy Manning Memoli, Pharm D
Tsampika (Beka) Apostolidis

EDS/Provider Synergies

Chris Andrews
Joy DeNardo
Ellen Arce

Opening remarks:

Dr. Sherter made the following announcements:

- The P & T Committee member position for Practicing Visiting Nurse, Psychiatric has been filled by Elizabeth Rodriguez, R.N. Elizabeth is currently the Assistant Director of Behavioral Health at New England Home Care and is also a Certified Legal Nurse Consultant.
- Dr. Kenneth Marcus has retired from the Department of Mental Health and Addiction Services.

Approval of minutes:

Committee members approved the meeting minutes from the September 3, 2009 meeting.

New Generics:

Chris Andrews informed the committee members regarding the following new generic products:

- The generics for Benzaclin (benzoyl peroxide/clindamycin), Allegra-D 12 hour (fexofenadine-D 12 hour), Prevacid (lansoprazole), Starlix (nateglinide), Aceon (perindopril), Restoril 7.5mg (temazepam 7.5mg) and Ultram ER (tramadol ER) were recommended to be non-preferred on the Medicaid PDL.
- The generics for Starlix (nateglinide) and Restoril 7.5mg (temazepam 7.5mg) were recommended to be non-preferred on the ConnPACE/SAGA PDL.
- The generics currently listed as preferred in the Beta Blocker class will be expanded to include generic Beta Blocker/Diuretic combinations. The following products were recommended to be preferred on the Medicaid PDL: atenolol/chlorthalidone, bisoprolol/hctz, metoprolol/hctz, and nadolol/bendroflumethiazide.

The Committee motioned to approve and accepted Provider Synergies' recommendations. The motion was passed unanimously.

Therapeutic Class Reviews:

Chris Andrews, from Provider Synergies, presented clinical data and financial analysis, as well as answered questions from committee members on the following fourteen therapeutic classes. The recommendations for each PDL will be listed with the class review and the PDL status will be distinguished by program name, with the products that differ between the two PDLs italicized. Outcomes and votes are recorded below by class:

Analgesics/Anesthetics, Topical

Chris Andrews presented the evaluation and recommendation for this class. He noted that this was a new class being added to the PDL and that there has been no new clinical information in the past year. The recommendations for the Medicaid PDL would be the addition of Flector, Lidoderm and Voltaren gel as preferred. Dr. Silberman motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL with Emmett Sullivan seconding. The motion was passed unanimously. The recommendations for the ConnPACE/SAGA PDL are that no products are preferred and Flector, Lidoderm and Voltaren gel are non-preferred. Larry Sobel motioned to approve and accept Provider Synergies' recommendations with the addition of Lidoderm as preferred for the ConnPACE/SAGA PDL with Dr. Thompson seconding. The motion was passed unanimously.

ON Medicaid PDL: *Flector, Lidoderm, Voltaren gel*

OFF Medicaid PDL: None

ON ConnPACE/SAGA PDL: Lidoderm

OFF ConnPACE/SAGA PDL: *Flector, Voltaren gel*

Angiotensin Modulators/CCB Combinations

Chris Andrews presented the evaluation and recommendation for this class. He noted that Exforge HCT is a new product in this class with similar contraindications, warnings and adverse events to Exforge. The ACCOMPLISH trial showed a 19% risk of CV events reduction with Lotrel compared to Benicar HCT. Other recent studies have validated the increased effectiveness of combination agents compared to monotherapy. Larry Sobel questioned the recommendations for excluding Tarka from the Medicaid PDL while including Tarka on the ConnPACE/SAGA PDL. Chris explained that while the clinical evaluations are the same for both PDLs there are differences in the financial evaluations which may result in different recommendations. The recommended changes to this class for the Medicaid PDL would be the addition of Exforge HCT and Lotrel and the removal of amlodipine/benazepril. Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL with Dr. Silberman seconding. The motion was passed with Larry Sobel abstaining. The recommendations for the ConnPACE/SAGA PDL are that Exforge/Exforge HCT, Lotrel, and Tarka are preferred and amlodipine/benazepril and Azor are non-preferred. Larry Sobel motioned to approve and accept Provider Synergies' recommendations as presented for the ConnPACE/SAGA PDL with Emmett Sullivan seconding. The motion was passed unanimously.

ON Medicaid PDL: Exforge/Exforge HCT, Lotrel

OFF Medicaid PDL: amlodipine/benazepril, Azor, *Tarka*

ON ConnPACE/SAGA PDL: Exforge/Exforge HCT, Lotrel, *Tarka*

OFF ConnPACE/SAGA PDL: amlodipine/benazepril, Azor

Antibiotics, GI

Chris Andrews presented the evaluation and recommendation for this class. He noted that Tindamax is now available as a generic, tinidazole. The recommended changes to this class for the Medicaid PDL would be the addition of tinidazole as preferred. Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL with Dr. Silberman seconding. The motion was passed unanimously. The recommendations for the ConnPACE/SAGA PDL are that metronidazole, neomycin and tinidazole are preferred and Alinia, Flagyl ER, Tindamax, Vancocin and Xifaxan are non-preferred. Dr. Silberman motioned to approve and accept Provider Synergies' recommendations as presented for the ConnPACE/SAGA PDL with Emmett Sullivan seconding. The motion was passed unanimously.

ON Medicaid PDL: *Alinia*, metronidazole, neomycin, *Tindamax*, tinidazole

OFF Medicaid PDL: Flagyl ER, Vancocin, Xifaxan

ON ConnPACE/SAGA PDL: metronidazole, neomycin, tinidazole

OFF ConnPACE/SAGA PDL: *Alinia*, Flagyl ER, *Tindamax*, Vancocin, Xifaxan

Antibiotics, Vaginal

Chris Andrews presented the evaluation and recommendation for this class. He noted that there has been no new clinical information since the last review. The recommended changes to this class for the Medicaid PDL would be the addition of Vandazole as preferred. Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL with Dr. Thompson seconding. The motion was passed unanimously. The recommendations for the ConnPACE/SAGA PDL are that clindamycin, metronidazole and Vandazole are preferred and Cleocin and Clindesse are non-preferred. Dr. Silberman motioned to approve and accept Provider Synergies' recommendations as presented for the ConnPACE/SAGA PDL with Dr. Slivka seconding. The motion was passed unanimously.

ON Medicaid PDL: *Cleocin*, clindamycin, *Clindesse*, metronidazole, Vandazole

OFF Medicaid PDL: None

ON ConnPACE/SAGA PDL: clindamycin, metronidazole, Vandazole

OFF ConnPACE/SAGA PDL: *Cleocin*, *Clindesse*

Bronchodilators, Anticholinergics

Chris Andrews presented the evaluation and recommendation for this class. He noted that the FDA has reviewed preliminary data from UPLIFT and has confirmed that there was no increased risk of stroke with Spiriva compared to placebo. The recommended change for this class for the Medicaid PDL would be the removal of Atrovent inhaler CFC version due to its discontinuation. Stella Cretella motioned to approve and accept Provider Synergies' recommendations for the Medicaid PDL as presented with Dr. Thompson seconding. The motion was passed unanimously. The recommendations for the ConnPACE/SAGA PDL are that Atrovent HFA, Combivent, ipratropium nebulizer solution, ipratropium/albuterol nebulizer solution, and Spiriva are preferred. Stella Cretella motioned to approve and accept Provider Synergies' recommendations for the ConnPACE/SAGA PDL as presented with Dr. Thompson seconding. The motion was passed unanimously.

ON Medicaid PDL: Atrovent HFA, Combivent, ipratropium nebulizer solution, ipratropium/albuterol nebulizer solution, Spiriva

OFF Medicaid PDL: None

ON ConnPACE/SAGA PDL: Atrovent HFA, Combivent, ipratropium nebulizer solution, ipratropium/albuterol nebulizer solution, Spiriva

OFF ConnPACE/SAGA PDL: None

Bronchodilators, Beta-Agonists

Chris Andrews presented the evaluation and recommendation for this class. He noted that the use of CFC propellants in inhalers has been phased out. The recommended change for this class for the Medicaid PDL would be the removal of albuterol inhaler CFC formulation due to its discontinuation. Dr. Silberman motioned to approve and accept Provider Synergies' recommendations for the Medicaid PDL as presented with Stella Cretella seconding. The motion was passed unanimously. The recommendations for the ConnPACE/SAGA PDL are that albuterol nebulizer solution, albuterol (oral), metaproterenol (oral), and Proventil HFA are preferred and albuterol low-dose nebulizer solution, Brovana, Foradil, levalbuterol, Maxair, Perforomist, Proair HFA, Serevent, Ventolin HFA, Xopenex solution, and Xopenex HFA are non-preferred. Stella Cretella motioned to approve and accept Provider Synergies' recommendations for the ConnPACE/SAGA PDL as presented with Emmett Sullivan seconding. The motion was passed unanimously.

ON Medicaid PDL: *albuterol low-dose nebulizer solution*, albuterol nebulizer solution, albuterol (oral), *Foradil*, *Maxair*, metaproterenol (oral), *Proair HFA*, Proventil HFA, *Serevent*, *terbutaline*, *Ventolin HFA*, *Xopenex solution*

OFF Medicaid PDL: Brovana, levalbuterol, Perforomist, Xopenex HFA

ON ConnPACE/SAGA PDL: albuterol nebulizer solution, albuterol (oral), metaproterenol (oral), Proventil HFA

OFF ConnPACE/SAGA PDL: *albuterol low-dose nebulizer solution*, Brovana, *Foradil*, levalbuterol, *Maxair*, Perforomist, *Proair HFA*, *Serevent*, *terbutaline*, *Ventolin HFA*, *Xopenex solution*, Xopenex HFA

Hypoglycemics, Insulins and Related Agents

Chris Andrews presented the evaluation and recommendation for this class. He noted that the 2009 update to the ADA consensus algorithm continues to list insulin products as treatment options following metformin and lifestyle interventions. He also noted that Apidra is indicated for use in pediatric patients with type 1 diabetes from ages 4-17. The recommended changes for this class for the Medicaid PDL would be the addition of Levemir, Novolin, Novolog and Novolog Mix as preferred. Dr. Silberman motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL with Dr. Thompson seconding. The motion was passed unanimously. The recommendations for the ConnPACE/SAGA PDL are that Levemir, Novolin, Novolog and Novolog Mix are preferred and Apidra, Humalog, Humalog Mix, Humulin and Lantus are non-preferred. Dr. Einstein motioned to approve and accept Provider Synergies' recommendations with the addition of all Lantus formulations for the ConnPACE/SAGA PDL with Larry Sobel seconding. The motion was passed unanimously.

ON Medicaid PDL: *Humalog, Humalog Mix, Humulin, Lantus, Levemir, Novolin, Novolog, Novolog Mix*

OFF Medicaid PDL: *Apidra*

ON ConnPACE/SAGA PDL: *Lantus, Levemir, Novolin, Novolog, Novolog Mix*

OFF ConnPACE/SAGA PDL: *Apidra, Humalog, Humalog Mix, Humulin*

Leukotriene Receptor Antagonists

Chris Andrews presented the evaluation and recommendation for this class. He noted that the FDA has recommended precautions in the labeling for these products that discuss the possibility of neuropsychiatric events. There are no recommended changes to this class for the Medicaid PDL. Stella Cretella motioned to approve and accept Provider Synergies' recommendations for the Medicaid PDL as presented with Dr. Silberman seconding. The motion was passed unanimously. The recommendations for the ConnPACE/SAGA PDL are that Accolate, Singulair, and Zylflo CR are preferred. Stella Cretella motioned to approve and accept Provider Synergies' recommendations for the ConnPACE/SAGA PDL as presented with Dr. Silberman seconding. The motion was passed unanimously.

ON Medicaid PDL: *Accolate, Singulair*

OFF Medicaid PDL: *Zylflo CR*

ON ConnPACE/SAGA PDL: *Accolate, Singulair, Zylflo CR*

OFF ConnPACE/SAGA PDL: *None*

Ophthalmic Antibiotics

Chris Andrews presented the evaluation and recommendation for this class. He noted that this class will contain products from the merged classes of Ophthalmics, Antibiotics and Ophthalmics, Fluoroquinolones and Macrolides. He also noted that Besivance is a new product in this class with similar contraindications, warnings and adverse events to other ophthalmic fluoroquinolones. The recommendations for the Medicaid PDL are that AzaSite, bacitracin, bacitracin/polymyxin, Besivance, erythromycin, gentamicin, Iquix, neomycin/polymyxin/gramicidin, polymyxin/trimethoprim, Quixin, sulfacetamide, tobramycin, Tobrex ointment, triple antibiotic, and Vigamox are preferred and Ciloxan ointment, ciprofloxacin solution, Natacyn, ofloxacin, Tobrex solution, and Zymar are non-preferred. Stella Cretella motioned to approve and accept Provider Synergies' recommendations for the Medicaid PDL as presented with Dr. Silberman seconding. The motion was passed unanimously. The recommendations for the ConnPACE/SAGA PDL are that AzaSite, bacitracin, bacitracin/polymyxin, Besivance, erythromycin, gentamicin, neomycin/polymyxin/gramicidin, polymyxin/trimethoprim, sulfacetamide, tobramycin, Tobrex ointment, and triple antibiotic are preferred and Ciloxan ointment, ciprofloxacin solution, Iquix, Natacyn, ofloxacin, Quixin, Tobrex solution, Vigamox, and Zymar are non-preferred. Dr. Silberman motioned to approve and accept Provider Synergies' recommendations for the ConnPACE/SAGA PDL as presented with Stella Cretella seconding. The motion was passed unanimously.

ON Medicaid PDL: AzaSite, bacitracin, bacitracin/polymyxin, Besivance, erythromycin, gentamicin, *Iquix*, neomycin/polymyxin/gramicidin, polymyxin/trimethoprim, *Quixin*, sulfacetamide, tobramycin, Tobrex ointment, triple antibiotic, *Vigamox*

OFF Medicaid PDL: Ciloxan ointment, ciprofloxacin solution, Natacyn, ofloxacin, Tobrex solution, Zymar

ON ConnPACE/SAGA PDL: AzaSite, bacitracin, bacitracin/polymyxin, Besivance, erythromycin, gentamicin, neomycin/polymyxin/gramicidin, polymyxin/trimethoprim, sulfacetamide, tobramycin, Tobrex ointment, triple antibiotic

OFF ConnPACE/SAGA PDL: Ciloxan ointment, ciprofloxacin solution, *Iquix*, Natacyn, ofloxacin, *Quixin*, Tobrex solution, *Vigamox*, Zymar

Ophthalmics, Allergic Conjunctivitis

Chris Andrews presented the evaluation and recommendation for this class. He noted that Bepreve is a new product in this class indicated for itching associated with allergic conjunctivitis. He also noted that Acular and Optivar are now available as generics. The recommended changes to this class for the Medicaid PDL would be the addition of Acular, Elestat, and Emadine and the removal of ketotifen and Optivar. Stella Cretella motioned to approve and accept Provider Synergies' recommendations for the Medicaid PDL as presented with Dr. Silberman seconding. The motion was passed unanimously. The recommendations for the ConnPACE/SAGA PDL are that Acular, Alomide, Alrex, cromolyn, Emadine, and Optivar are preferred and Alamast, Alocril, azelastine, Bepreve, Elestat, ketorolac, Pataday, and Patanol are non-preferred. Dr. Einstein motioned to approve and accept Provider Synergies' recommendations for the ConnPACE/SAGA PDL with the addition of Patanol as preferred with Dr. Silberman seconding. The motion was passed unanimously.

ON Medicaid PDL: Acular, *Alamast*, Alrex, cromolyn, *Elestat*, Emadine, *Pataday*, Patanol

OFF Medicaid PDL: Alocril, *Alomide*, azelastine, Bepreve, ketorolac, ketotifen, *Optivar*

ON ConnPACE/SAGA PDL: Acular, *Alomide*, Alrex, cromolyn, Emadine, *Optivar*, Patanol

OFF ConnPACE/SAGA PDL: *Alamast*, Alocril, azelastine, Bepreve, *Elestat*, ketorolac, *Pataday*

Ophthalmics, Glaucoma Agents

Chris Andrews presented the evaluation and recommendation for this class. He noted that Alphagan P is now available as a generic, brimonidine P. The recommended changes to this class for the Medicaid PDL would be the addition of Cosopt and Trusopt and the removal of dipivefrin, dorzolamide, dorzolamide/timolol, and Lumigan. Stella Cretella motioned to approve and accept Provider Synergies' recommendations for the Medicaid PDL as presented with Dr. Silberman seconding. The motion was passed unanimously. The recommendations for the ConnPACE/SAGA PDL are that Alphagan P, Azopt, betaxolol, Betimol, Betoptic S, brimonidine, carteolol, Cosopt, levobunolol, Lumigan, metipranolol, pilocarpine, Propine, timolol, Travatan/Travatan Z, Trusopt, and Xalatan are preferred and brimonidine P, Combigan, dipivefrin, dorzolamide, dorzolamide/timolol, and Istalol are non-preferred. Emmett Sullivan motioned to approve and accept Provider Synergies' recommendations for the ConnPACE/SAGA PDL as presented with Dr. Silberman seconding. The motion was passed unanimously.

ON Medicaid PDL: Alphagan P, Azopt, betaxolol, brimonidine, carteolol, *Combigan*, Cosopt, *Istalol*, levobunolol, metipranolol, pilocarpine, timolol, Travatan/Travatan Z, Trusopt, Xalatan

OFF Medicaid PDL: *Betimol*, *Betoptic S*, brimonidine P, dipivefrin, dorzolamide, dorzolamide/timolol, *Lumigan*, *Propine*

ON ConnPACE/SAGA PDL: Alphagan P, Azopt, betaxolol, *Betimol*, *Betoptic S*, brimonidine, carteolol, Cosopt, levobunolol, *Lumigan*, metipranolol, pilocarpine, *Propine*, timolol, Travatan/Travatan Z, Trusopt, Xalatan

OFF ConnPACE/SAGA PDL: brimonidine P, *Combigan*, dipivefrin, dorzolamide, dorzolamide/timolol, *Istalol*

Pancreatic Enzymes

Chris Andrews presented the evaluation and recommendation for this class. He noted that this was a new class being added to the PDL. He also noted that the FDA required manufacturers of pancreatic enzyme drug products to submit new drug applications by April 2009 with the intent of giving approval by April 2010. At this time only Zenpep and Creon have obtained FDA approval, although several other products are awaiting decisions. The recommendations for the Medicaid PDL are that Creon, Pancrease MT, Pancrecarb MS, pancrelipase, Ultrase, and Viokase are preferred. Stella Cretella motioned to approve and accept Provider Synergies' recommendations for the Medicaid PDL as presented with Dr. Thompson seconding. The motion was passed unanimously. The recommendations for the ConnPACE/SAGA PDL are that Creon, Pancrease MT, pancrelipase, Ultrase, and Viokase are preferred and Pancrecarb MS is non-preferred. Stella Cretella motioned to approve and accept Provider Synergies' recommendations for the ConnPACE/SAGA PDL as presented with Dr. Silberman seconding. The motion was passed unanimously.

ON Medicaid PDL: Creon, Pancrease MT, *Pancrecarb MS*, pancrelipase, Ultrase, Viokase

OFF Medicaid PDL: None

ON ConnPACE/SAGA PDL: Creon, Pancrease MT, pancrelipase, Ultrase, Viokase

OFF ConnPACE/SAGA PDL: *Pancrecarb MS*

Phosphate Binders

Chris Andrews presented the evaluation and recommendation for this class. He noted that Genzyme has indefinitely postponed the removal of Renagel from the market and that Renvela is now available in a packet for administration after it is mixed with water. He also noted that Eliphos is a new product in this class with contraindications, warnings, drug interactions and adverse events similar to those of PhosLo. The recommended change to this class for the Medicaid PDL is the removal of Fosrenol. Stella Cretella motioned to approve and accept Provider Synergies' recommendations for the Medicaid PDL as presented with Dr. Silberman seconding. The motion was passed with Larry Sobel abstaining and Elizabeth Rodriguez voting against. The recommendations for the ConnPACE/SAGA PDL are that PhosLo and Renagel are preferred and calcium acetate, Eliphos, Fosrenol, and Renvela are non-preferred. Stella Cretella motioned to approve and accept Provider Synergies' recommendations for the ConnPACE/SAGA PDL as presented with Dr. Einstein seconding. The motion was passed with Larry Sobel abstaining and Elizabeth Rodriguez voting against.

ON Medicaid PDL: PhosLo, Renagel

OFF Medicaid PDL: calcium acetate, Eliphos, Fosrenol, Renvela

ON ConnPACE/SAGA PDL: PhosLo, Renagel

OFF ConnPACE/SAGA PDL: calcium acetate, Eliphos, Fosrenol, Renvela

Platelet Aggregation Inhibitors

Chris Andrews presented the evaluation and recommendation for this class. He noted that Effient is a new product in this class indicated for the reduction of thrombotic events in select populations of patients with acute coronary syndrome who are to be managed with percutaneous coronary interventions. He also noted that several studies have reported an increased risk of cardiovascular events associated with concurrent use of Plavix and proton pump inhibitors. The recommended change to this class for the Medicaid PDL is the removal of Aggrenox. Dr. Silberman motioned to approve and accept Provider Synergies' recommendations for the Medicaid PDL with Dr. Thompson seconding. The motion was passed unanimously. The recommendations for the ConnPACE/SAGA PDL are that dipyridamole and Plavix are preferred and Aggrenox, Effient, and ticlopidine are non-preferred. Dr. Silberman motioned to approve and accept Provider Synergies' recommendations for the ConnPACE/SAGA PDL as presented with Stella Cretella seconding. The motion was passed unanimously.

ON Medicaid PDL: dipyridamole, Plavix

OFF Medicaid PDL: Aggrenox, Effient, ticlopidine

ON ConnPACE/SAGA PDL: dipyridamole, Plavix

OFF ConnPACE/SAGA PDL: Aggrenox, Effient, ticlopidine

Other Business:

Dr. Slivka questioned the clarity of preferred products on the PDL when the brand is preferred and the generic is non-preferred. Jason Gott explained that the prescriber does not need to write a "Brand Medically Necessary" prescription in these instances and offered to distribute a bulletin to address pharmacy billing clarification for brand-named medications on the PDL.

Dr. Thompson inquired when the last provider satisfaction survey was done in regards to our PA process and PDL. Evelyn Dudley replied that the Medicaid Managed Care Council was currently in the process of assembling a survey for distribution to providers.

Recommendations for next class reviews:

Provider Synergies recommended the following classes be reviewed at the next P&T meeting:

- Acne Agents, Topical
- Antidepressants, Other
- Antidepressants, SSRI
- Antihistamines, Minimally Sedating
- Antipsychotics
- Bone Resorption Suppression & Related Agents
- Calcium Channel Blockers
- Erythropoiesis Stimulating Proteins
- Growth Hormone
- Intranasal Rhinitis Agents
- NSAIDS
- Otic Fluoroquinolones
- Proton Pump Inhibitors
- Skeletal Muscle Relaxants
- Stimulants & Related Agents
- Ulcerative Colitis Agents

Schedule next year's P & T Committee meetings:

Committee members agreed on the following dates for 2010:

- March 4, 2010
- June 3, 2010
- September 2, 2010
- December 2, 2010

Meeting adjourned at 7:45pm